AstraZeneca PLC Stock Forecast for 2023 - 2025 - 2030
Updated on 05/20/2024
AstraZeneca PLC Stock Forecast and Price Target
AstraZeneca PLC has an average price target of £163.05 recently offered by sixteen notable experts for 2024, which would represent a potential upside of approximately 34.64% from the last closing price in May, 2024 if reached. This potential increase is based on a high estimate of £220.19 and a low estimate of £131.28. If you're looking to buy AstraZeneca PLC stock, you may also want to check out its rivals.
34.64% Upside
AstraZeneca PLC Fair Value Forecast for 2023 - 2025 - 2030
AstraZeneca PLC's Price has decreased In the last four years, from £69.51 to £0.00 – a 100.00% drop. In the next year, analysts predict that Fair Value will reach £140.05 – an increase of 100.00%. For the next seven years, the forecast is for Fair Value to grow by 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| LLY Stock Forecast | Eli Lilly and | Outperform |
16
|
$770.00 | $636.99 | 13.96% |
| NOVO B Stock Forecast | Novo Nordisk A/S | Outperform |
12
|
kr903.30 | kr696.07 | 6.55% |
| JNJ Stock Forecast | Johnson & Johnson | Outperform |
9
|
$154.64 | $174.55 | 9.93% |
| MRK Stock Forecast | Merck | Outperform |
2
|
$131.19 | $130.51 | 9.00% |
| ABBV Stock Forecast | AbbVie | Outperform |
9
|
$166.42 | $178.42 | 9.66% |
AstraZeneca PLC Revenue Forecast for 2023 - 2025 - 2030
AstraZeneca PLC's Revenue has grown in the last three years, jumping from £26.62B to £45.81B – an increase of 72.11%. In the next year, analysts predict that Revenue will reach £50.38B – an increase of 9.98%. For the next seven years, the forecast is for Revenue to grow by 41.93%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| NOVN Stock Forecast | Novartis | Hold |
10
|
CHF93.37 | CHF105.00 | 15.26% |
| ABT Stock Forecast | Abbott Laboratories | Outperform |
9
|
$104.09 | $118.92 | 21.53% |
| AMGN Stock Forecast | Amgen | Outperform |
4
|
$312.47 | $303.65 | 2.41% |
AstraZeneca PLC Dividend per Share Forecast for 2023 - 2025 - 2030
In the last three years, AstraZeneca PLC's Dividend per Share has increased by 3.57%, going from £2.80 to £2.90. In the next year, analysts are expecting an increase in Dividend per Share, predicting it will reach £3.16 – an increase of 8.97%. The AstraZeneca PLC forecast is for Dividend per Share to reach £5.28 or grow by 82.07%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| MDT Stock Forecast | Medtronic | Outperform |
11
|
$85.92 | $92.47 | 11.73% |
| GSK Stock Forecast | GSK | Outperform |
12
|
£17.75 | £17.30 | 12.39% |
| CSL Stock Forecast | CSL | Outperform |
12
|
$280.00 | $205.51 | -26.66% |
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| BMY Stock Forecast | Bristol-Myers Squibb | Hold |
2
|
$44.03 | $58.15 | 22.64% |
| GILD Stock Forecast | Gilead Sciences Inc | Outperform |
11
|
$67.72 | $87.82 | 18.13% |
| MRK Stock Forecast | Merck KGaA | Outperform |
18
|
167.20€ | 190.06€ | 9.45% |
AstraZeneca PLC EBITDA Forecast for 2023 - 2025 - 2030
AstraZeneca PLC's EBITDA has increased by 121.91% In the last three years, going from £6.76B to £15.01B. In the next year, analysts expect EBITDA to reach £18.11B – an increase of 20.62%. For the next seven years, the forecast is for EBITDA to grow by 49.72%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| BDX Stock Forecast | Becton Dickinson and Co | Outperform |
9
|
$236.30 | $284.47 | 17.44% |
| 4568 Stock Forecast | Daiichi Sankyo Company | Buy |
4
|
¥5.53k | ¥5.24k | 7.58% |
| MMM Stock Forecast | 3M | Hold |
10
|
$105.26 | $109.39 | -1.67% |
AstraZeneca PLC EBIT Forecast for 2023 - 2025 - 2030
In the last three years, AstraZeneca PLC's EBIT has grown, increasing from £4.15B to £10.43B – a growth of 151.54%. The next year looks promising for AstraZeneca PLC, with analysts predicting EBIT of £17.26B – an increase of 65.42%. Over the next seven years, experts anticipate that AstraZeneca PLC's EBIT will grow at a rate of 152.82%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| 4519 Stock Forecast | Chugai Pharmaceutical | Outperform |
6
|
¥5.01k | ¥4.92k | 21.83% |
| MRNA Stock Forecast | Moderna | Outperform |
16
|
$132.90 | $135.42 | -5.19% |
| BAS Stock Forecast | BASF | Outperform |
12
|
48.88€ | 49.50€ | 14.57% |
AstraZeneca PLC EPS Price Prediction Forecast for 2023 - 2025 - 2030
AstraZeneca PLC's EPS has decreased In the last four years, from £4.02 to £0.00 – a 100.00% drop. In the next year, analysts predict that EPS will reach £8.10 – an increase of 100.00%. For the next seven years, the forecast is for EPS to grow by 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| LONN Stock Forecast | Lonza Group | Buy |
16
|
CHF529.20 | CHF516.89 | 13.38% |
| CTVA Stock Forecast | Corteva | Outperform |
12
|
$56.45 | $61.72 | 15.15% |
| BIIB Stock Forecast | Biogen | Outperform |
10
|
$230.57 | $299.62 | 25.12% |